BI 207127 placebo

DRUG2 trials

Sponsors

Presidio Pharmaceuticals, Inc., Boehringer Ingelheim

Conditions

Chronic Hepatitis CHealthy

Phase 1

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

CompletedNCT01965431

Boehringer IngelheimHealthy

Start: 2013-10-31End: 2014-01-31Updated: 2016-04-14

Phase 2

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

CompletedNCT01859962

Presidio Pharmaceuticals, Inc.Chronic Hepatitis C

Start: 2013-05-31End: 2014-12-31Updated: 2015-11-25